Cover Image
市場調查報告書

PharmAbcine, Inc.:產品平台分析

PharmAbcine Inc - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 293898
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
PharmAbcine, Inc.:產品平台分析 PharmAbcine Inc - Product Pipeline Review - 2016
出版日期: 2016年12月30日 內容資訊: 英文 38 Pages
簡介

PharmAbcine, Inc.是總公司設立於韓國的生物科技企業,正在從事人類用單株抗體的藥物研究·開發。該公司臨床正在開發產品有Lead MAb及雙特異性MAb,適用領域有癌症,發炎疾病等。

本報告提供PharmAbcine, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

PharmAbcine, Inc. 的基本資料

  • PharmAbcine, Inc. 概要
  • 主要資訊
  • 企業資料

PharmAbcine, Inc. :R&D概要

  • 主要的治療範圍

PharmAbcine, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

PharmAbcine, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

PharmAbcine, Inc. :藥物簡介

  • TTAC-0001
  • PMC-001
  • PMC-002
  • PMC-201
  • Monoclonal Antibody to Antagonize c-Met for Cancer and Inflammatory Disorders
  • Monoclonal Antibody to Antagonize EGFR for Cancer and Inflammatory Disorders
  • Monoclonal Antibody to Antagonize HER2 for Cancer and Inflammatory Disorders
  • Monoclonal Antibody to Antagonize IGFR-1 for Cancer and Inflammatory Disorders
  • Monoclonal Antibody to Antagonize VEGFR-1 for Cancer and Inflammatory Disorders
  • Monoclonal Antibody to Antagonize VEGFR-3 for Cancer and Inflammatory Disorders
  • Monoclonal Antibody to Inhibit DLL4 for Cancer and Inflammatory Disorders
  • Monoclonal Antibody to Inhibit EPCAM for Cancer and Inflammatory Disorders
  • Monoclonal Antibody to Target CD-20 for Cancer and Inflammatory Disorders

PharmAbcine, Inc. :開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

PharmAbcine, Inc. :最新的開發平台資訊

PharmAbcine, Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08191CDB

Summary

Global Markets Direct's, 'PharmAbcine Inc - Product Pipeline Review - 2016', provides an overview of the PharmAbcine Inc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by PharmAbcine Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of PharmAbcine Inc
  • The report provides overview of PharmAbcine Inc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses PharmAbcine Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features PharmAbcine Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate PharmAbcine Inc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for PharmAbcine Inc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding PharmAbcine Inc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • PharmAbcine Inc Snapshot
    • PharmAbcine Inc Overview
    • Key Facts
  • PharmAbcine Inc - Research and Development Overview
    • Key Therapeutic Areas
  • PharmAbcine Inc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • PharmAbcine Inc - Pipeline Products Glance
    • PharmAbcine Inc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • PharmAbcine Inc - Drug Profiles
    • Monoclonal Antibody to Antagonize c-Met for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize EGFR for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize HER2 for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize VEGFR-1 for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize VEGFR-3 for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit DLL4 for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit EPCAM for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Target CD-20 for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMC-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMC-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMC-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTAC-0001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • PharmAbcine Inc - Pipeline Analysis
    • PharmAbcine Inc - Pipeline Products by Target
    • PharmAbcine Inc - Pipeline Products by Route of Administration
    • PharmAbcine Inc - Pipeline Products by Molecule Type
    • PharmAbcine Inc - Pipeline Products by Mechanism of Action
  • PharmAbcine Inc - Dormant Projects
  • PharmAbcine Inc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • PharmAbcine Inc, Key Facts
  • PharmAbcine Inc - Pipeline by Indication, 2016
  • PharmAbcine Inc - Pipeline by Stage of Development, 2016
  • PharmAbcine Inc - Monotherapy Products in Pipeline, 2016
  • PharmAbcine Inc - Preclinical, 2016
  • PharmAbcine Inc - Discovery, 2016
  • PharmAbcine Inc - Pipeline by Target, 2016
  • PharmAbcine Inc - Pipeline by Route of Administration, 2016
  • PharmAbcine Inc - Pipeline by Molecule Type, 2016
  • PharmAbcine Inc - Pipeline Products by Mechanism of Action, 2016
  • PharmAbcine Inc - Dormant Developmental Projects,2016
  • PharmAbcine Inc, Other Locations

List of Figures

  • PharmAbcine Inc - Pipeline by Top 10 Indication, 2016
  • PharmAbcine Inc - Pipeline by Stage of Development, 2016
  • PharmAbcine Inc - Monotherapy Products in Pipeline, 2016
  • PharmAbcine Inc - Pipeline by Top 10 Target, 2016
  • PharmAbcine Inc - Pipeline by Molecule Type, 2016
  • PharmAbcine Inc - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top